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Abstract
Background: Avian beta-defensins (AvBD) are small, cationic, antimicrobial peptides. The potential application of
AvBDs as alternatives to antibiotics has been the subject of interest. However, the mechanisms of action remain to
be fully understood. The present study characterized the structure-function relationship of AvBD-6 and AvBD-12,
two peptides with different net positive charges, similar hydrophobicity and distinct tissue expression profiles.
Results: AvBD-6 was more potent than AvBD-12 against E. coli, S. Typhimurium, and S. aureus as well as clinical
isolates of extended spectrum beta lactamase (ESBL)-positive E. coli and K. pneumoniae. AvBD-6 was more effective
than AvBD-12 in neutralizing LPS and interacting with bacterial genomic DNA. Increasing bacterial concentration
from 105 CFU/ml to 109 CFU/ml abolished AvBDs’ antimicrobial activity. Increasing NaCl concentration significantly
inhibited AvBDs’ antimicrobial activity, but not the LPS-neutralizing function. Both AvBDs were mildly chemotactic
for chicken macrophages and strongly chemotactic for CHO-K1 cells expressing chicken chemokine receptor 2
(CCR2). AvBD-12 at higher concentrations also induced chemotactic migration of murine immature dendritic cells
(DCs). Disruption of disulfide bridges abolished AvBDs’ chemotactic activity. Neither AvBDs was toxic to CHO-K1,
macrophages, or DCs.
Conclusions: AvBDs are potent antimicrobial peptides under low-salt conditions, effective LPS-neutralizing agents,
and broad-spectrum chemoattractant peptides. Their antimicrobial activity is positively correlated with the peptides’
net positive charges, inversely correlated with NaCl concentration and bacterial concentration, and minimally
dependent on intramolecular disulfide bridges. In contrast, their chemotactic property requires the presence of
intramolecular disulfide bridges. Data from the present study provide a theoretical basis for the design of AvBD-
based therapeutic and immunomodulatory agents.
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beta-defensin; BSA, Bovine serum albumin; C.I., Chemotaxis index; CD, Circular dichroism; CFU, Colony-forming unit;
DCs, Dendritic cells; FBS, Fetal bovine serum; fMLF, N-Formyl-methionyl-leucyl-phenylalanine; Fmoc, 9-fluorenyl-
methoxycarbonyl; GFP, Green fluorescent protein; GM-CSF, Granulocyte macrophage colony-stimulating factor; HRP,
Horseradish peroxidase; Ig, immunogluobin; LB, Luria-Bertani; LPS, Lipopolysaccharides; LTA, Lipoteichoic acid; MIC,
(Continued on next page)
* Correspondence: zhangshup@missouri.edu
1Department of Veterinary Pathobiology, University of Missouri, Columbia,
MO, USA
4Department of Veterinary Pathobiology, Veterinary Medical Diagnostic
Laboratory, College of Veterinary Medicine, University of Missouri, Columbia,
MO 65211, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yang et al. BMC Microbiology  (2016) 16:210 
DOI 10.1186/s12866-016-0828-y
(Continued from previous page)
Minimum inhibitory concentration; NADPH, Nicotinamide adenine dinucleotide phosphate; PBS, Phosphate buffered
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Background
Defensins are small cationic antimicrobial peptides con-
taining six disulfide-paired cysteines [1]. Based on the
sequence homology and connectivity of six conserved
cysteine residues, defensins are classified into three sub-
families: α-, β- and θ-defensins [2–4]. Due to the interest
in their potential application as antibiotic alternatives,
defensins of different host species have been extensively
investigated [5–8]. Although many defensins show
broad-spectrum antimicrobial activities against bacteria,
fungi, and some enveloped viruses, the mechanisms of
action remain to be fully understood [8–11]. The anti-
microbial mechanism of defensins primarily depends on
several structural features, such as cationic charge and
hydrophobicity, and is mainly divided into two classes,
membrane-disruption and intracellular target [6, 12].
The membrane-disruptive model has been attributed to
the electrostatic attraction between positively charged
amino acid residues and negatively charged microbial
membrane components (such as lipopolysaccharides
(LPS), lipoteichoic acid (LTA) and anionic phospho-
lipids) and insertion of hydrophobic residues into the
microbial membrane, resulting in membrane disruption
and cell death [10, 13]. Several models have been pro-
posed to support this mechanism, including the barrel-
stave, toroidal and carpet membrane pore-forming
models, and sinking raft transient pore forming model
[2, 14–18]. In addition to direct actions on microbial
membrane, several studies have revealed intracellular
functions of translocated antimicrobial peptides, such as
interfering with cytoplasmic membrane septum forma-
tion and cell-wall synthesis, binding to nucleic acids, and
inhibiting enzymes [2, 11, 15].
Defensins also contribute to adaptive immunity by che-
moattracting monocytes, T lymphocytes, dendritic cells
(DC) and mast cells to the site of infection, enhancing
macrophage phagocytosis, inducing pro-inflammatory cy-
tokines, and activating immature DCs [10, 11, 19]. The
chemotactic activities of human β-defensin 1 to 3 (hBD1-
3) as well as mouse β-defensin 2 (mBD2) are mediated by
chemokine receptor CCR2 and CCR6 [20–23]. Activation
of immature DCs by murine β-defensin-2 and avian β-
defensin-13 involves the Toll-like receptor 4-nuclear
factor-kappaB (TLR4-NFkB) signaling cascade [24, 25].
These activities enable β-defensins function as indigenous
vaccine adjuvants [26, 27].
The chicken genome contains 14 β-defensin genes, lo-
cated in a single defensin gene cluster on chromosome
3q3.5–3.7 [28, 29]. Some of these defensin peptides were
initially referred to as gallinacins (Gal). To be consistent with
the mammalian defensin nomenclature, the term of avian β-
defensin (AvBD) was adopted [29–31]. The first two avian
β-defensins, chicken AvBD-1 and AvBD-2, were isolated
from chicken leukocytes in 1994, and later an inducible
epithelially expressed avian β-defensin (AvBD-3) was re-
ported in 2001 [32–34]. Transcriptional analysis of AvBD
genes indicate that AvBD-1, −2, and −4 to −7 are mainly
of myeloid origin, whereas the remaining AvBD-3, and −8
to −14 are mainly from epithelial cells. Both myeloid and
epithelial AvBDs are expressed in a variety of other tissues
[28, 29, 34]. Although many AvBDs possess certain de-
grees of antimicrobial activity and some may interact with
immune cells, limited information is available regarding
the mechanisms of antimicrobial and immunomodulatory
activities [8, 11, 35]. In the present study, we have charac-
terized the contribution of charge and disulfide bridges to
various biological functions of AvBD-6 and AvBD-12
which are conserved in many avian species. While the
hydrophobicity of these AvBDs are similar, AvBD-12 has
the lowest average net positive charge and AvBD-6 has a
relatively high net positive charge [36].
Results
Antimicrobial activity of AvBD-6 and AvBD-12
Both AvBDs showed dose-dependent (1 to 128 μg/ml)
bactericidal activities against three common bacterial
pathogens, E. coli, S. Typhimurium, and S. aureus
(Fig. 1). To detect antimicrobial activity of AvBDs over a
wide range of concentrations, percentage killing of bac-
teria was evaluated. AvBD-6 was generally more potent
than AvBD-12 in killing E. coli (2 to 64 μg/ml), S. Typhi-
murium and S. aureus (8 to 128 μg/ml). The susceptibil-
ity of three bacterial pathogens to AvBDs (AvBD-6 at
lower concentrations and AvBD-12 at higher concentra-
tions) could be classified as: E. coli > S. Typhimurium >
S. aureus. The killing activities of AvBDs were impaired
by increasing NaCl concentration from 5 mM to 50 mM
or 150 mM (Fig. 1). The negative impact of increased
NaCl concentration could be summarized as follows:
AvBD-6/AvBD-12/E. coli > AvBD-6/S. Typhimurium >
AvBD-6/S. aureus >AvBD-12/S. Typhimuirum > AvBD-
12/S. aureus.
Since both AvBDs demonstrated significant killing activ-
ities at 32 μg/ml, this concentration was used to characterize
killing kinetics. Log reduction of bacterial colony-forming
unit (CFU) was used to define killing activity which enabled
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quantifying the number of bacteria killed when different
concentrations of inoculum were tested. Kinetics study indi-
cated that majority of the killing activity occurred within the
first 30 min of bacteria-AvBD interaction (Fig. 2). Killing ac-
tivity decreased significantly when bacterial inoculum con-
centration increased from 105 CFU/ml to 109 CFU/ml (p <
0.01). A comparison of the killing activities of both AvBDs
confirmed that AvBD-6 was more potent than AvBD-12.
The minimum inhibitory concentrations (MICs) of
both AvBDs against reference strains and clinical iso-
lates were above 128 μg/ml (Table 2). When a low-salt
Muller Hinton broth was used to determine MICs
(MIC-ls), much lower values were obtained. For ex-
ample, MIC-ls for AvBD-6 against ESBL-positive E. coli
and K. pneumoniae were 8 μg/ml and 6 μg/ml,
respectively.
Fig. 1 Antimicrobial activity of AvBD-6 and AvBD-12 against E. coli, S. Typhimurium and S. aureus. Bacteria (105 CFU/ml) were incubated with various
concentrations of AvBD-6 or AvBD-12 in the presence of 5 mM NaCl (■), 50 mM NaCl (▲), or 150 mM () at 37 °C for 3 h. a Antimicrobial activities of
AvBD-6. b Antimicrobial activities of AvBD-12. Antimicrobial activity was presented as percent of killing as compared to no-AvBD control. Data are
means of three independent experiments ± SD (n = 3). Asterisks indicate statistically significant difference between 5 mM and 50 mM and 150 mM of
NaCl (*p < 0.05, **p < 0.01)
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Ability of AvBD to neutralize LPS
Both AvBD-6 and AvBD-12 neutralized LPS activity in a
dose-dependent manner (Fig. 3a). At the concentration of
32 μg/ml, AvBDs were able to neutralize more than 70 %
of equal volume of 1 EU/ml of LPS. The neutralizing cap-
acity of AvBD-6 was significantly stronger (p < 0.05 or
0.01) than AvBD-12. While AvBD-6 (16 μg/ml) was more
effective in neutralizing E. coli LPS than Salmonella LPS,
AvBD-12 showed no difference in neutralizing E. coli LPS
and Salmonella LPS. Interestingly, NaCl concentrations,
ranging from 0.1 % (17.1 mM) to 0.8 % (137 mM), had no
impact on AvBDs’ ability to neutralize LPS (Fig. 3b).
Fig. 2 Killing kinetics of AvBD-6 and AvBD-12 against different bacterial concentrations. Bacteria (105, 107, and109 CFU/ml) were treated with
32 μg/ml of at 37 °C for various times. a Killing kinetics of AvBD-6. b Killing kinetics of AvBD-12. Log reduction of CFU at each time point for each
bacterial concentration was used to demonstrate the absolute number (relative to % killing) of bacteria by AvBDs. Data are presented as means ±
SD (n = 3). Asterisks denote significant difference (*p < 0.05, **p < 0.01) in killing activity of each AvBD between different bacterial concentrations:
105 CFU/ml (▲), 107 CFU/ml (■) and 109 CFU/ml (♦)
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Cell cytotoxicity
The cellular toxicity of AvBD-6 and AvBD-12 to chicken
macrophage cell line HD11 and MQ-NCSU, mouse im-
mature dendritic JAWSII cells, and hamster CHO-K1
cells were evaluated using a MTT cell proliferation assay
(Thermo Fisher Scientific). Exposure of cells to AvBDs
at concentrations of 4, 16, 64, 256 μg/ml for 4, 12, 24,
and 48 h did not cause any change in cell variability.
Data on the highest concentration (256 μg/ml) and lon-
gest exposure (48 h) were presented in Fig. 4.
Expression of CCR2-GFP/CCR6-GFP proteins in CHO-K1
cells
Fluorescent microscopy showed that CCR2-GFP fusion
protein (green fluorescence) was mainly located in the
cytoplasmic membrane of transfected CHO-K1 cells
Fig. 3 LPS-neutralizing activity of AvBD-6 and AvBD-12. LPS-neutralizing activities of AvBD-6 and AvBD-12 were determined by the Limulus Amoebocyte
Lysate (LAL) assay. a Neutralizing activities AvBD-6 (■) and AvBD-12 (▲) for E. coli O111:B4 LPS and S. Typhimurium L6143 LPS. b The effect of NaCl
concentration on the ability of AvBDs to neutralize E. coli O111:B4 LPS (■) and S. Typhimurium L6143 LPS (▲). The data are presented as means ± SD
(n = 3). Asterisks denote statistically significant difference in LPS-neutralizing activities between AvBD-6 and AvBD-12 (*p < 0.05, **p < 0.01)
Fig. 4 Cytotoxicity of AvBD-6 and AvBD-12 on host cells. Effect of 256 μg/ml AvBD-6 and AvBD-12 on the viability of chicken macrophages MQ-NCSU
and HD11 cells, mouse immature dendritic JAWSII, and hamster CHO-K1 cells at 4, 12, 24, 48 h of incubation. Results shown are percentages of viable
cells in different treatment groups relative to the untreated control cells. The data are expressed as the mean ± SD (n = 3)
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whereas CCR6-GFP was mostly found in the nuclear
membrane and GFP alone was visible throughout the
cytoplasm of CHO-K1 cells (Fig. 5a). Wild-type CHO-K1
cells did not show any green fluorescence. The expression
of CCR2 and CCR6 in transfected cells was confirmed by
RT-PCR which amplified the CCR2 and CCR6 genes with
the expected sizes (1,065 bp for CCR2 and 1,089 bp for
CCR6, shown in Fig. 5b). The expression of fusion pro-
teins (CCR2-GFP, 65 kDa; CCR6-GFP, 66 kDa) was also
confirmed by western blot analysis (Fig. 5c).
Chemotactic activity of AvBDs
Both AvBDs demonstrated relatively low chemotactic ac-
tivity for avian macrophage cell line MQ-NCSU (Fig. 6a).
At a high concentration (64 μg/ml), both AvBDs induced
the migration of murine immature dendritic cells
(JAWSII) and AvBD-12 was significantly more effective
than AvBD-6 in chemoattracting JAWSII cells (Fig. 6b).
Pretreatment of JAWSII cells with AvBDs significantly
inhibited subsequent cell migration towards AvBDs (p <
0.05), confirming that migration of JAWSII was induced
by AvBDs (Fig. 6c and d). Both AvBDs exhibited a dose-
dependent chemotactic effect on CCR2-CHO cells and no
difference in their chemoattractant activities was detected
(Fig. 6e). AvBD-6 also showed a dose-dependent chemo-
tactic activity for CCR6-CHO cells whereas AvBD-12
demonstrated minimal chemotactic activity for CCR6-
CHO (Fig. 6f).
The antimicrobial, chemotactic, and neutralizing LPS
activities of reduced AvBDs
To evaluate the role of disulfide bridges in antimicrobial
and chemotactic activities, AvBDs were reduced with a
thioredoxin system (Fig. 7a). When defensins were fully
reduced, the intramolecular disulfide bonds were broken
and peptides became denatured which increased the over-
all hydrophobic surface area, compared to wild-type pep-
tides with hydrophobic residues embedded inside.
Reversed-phase high performance liquid chromatography
(RP-HPLC) analysis of AvBDs following treatment with
various concentrations of thioredoxin revealed that AvBDs
were completely reduced by 4 μM thioredoxin as shown
by the increased retention time with peak shifts (Fig. 7a).
The structural changes due to removal of disulfide
bonds were confirmed by far-ultraviolet circular di-
chroism (CD). Wild-type AvBD-6 and AvBD-12 dis-
played a broad negative band at 205 nm and a small
negative shoulder at 216 nm, indicating a well-folded
peptides with intracellular β-sheet conformation
(Fig. 7b). In contrast, reduced AvBD-6 and AvBD-12
showed a significant negative signal around 195 nm,
indicating a random coil structure. In addition, re-
duced AvBD-12 also displayed a negative shoulder at
about 216 nm, which was likely caused by α-helix of
AvBD-12. Data from RP-HPLC and CD analyses indi-
cated that treatment with the thioredoxin system
broke the intramolecular disulfide bonds.
Fig. 5 Expression of chicken chemokine receptors CCR2 and CCR6 in CHO-K1 cells. a Fluorescence images of CCR2-GFP, CCR6-GFP and GFP proteins
(green) expressing CHO-K1 cells. Transfected cells were fixed with methanol: acetone (v:v, 1:1), and nuclei were stained with 0.1 μg/ml DAPI (blue). b
Gel electrophoresis of RT-PCR products of CCR2 (1,065 bp) and CCR6 (1,089 bp) derived from transfected CHO-K1 cells. GAPDH (125 bp) was included
as RT-PCR control. c Western-blotting analysis of the CCR2/CCR6-GFP fusion protein expressed in CHO-K1 cells. Wild-type and only GFP expressing
CHO-K1 cells were included as negative and positive controls, respectively. The protein fractions were probed with polyclonal goat anti-GFP primary
antibody (1:1000) and HRP-coupled anti-goat secondary antibody (1:500), and visualized after color development with 4-CN and 30 % hydrogen
peroxide. GFP-CCR2 is primarily located in the cytoplasmic membrane, GFP-CCR6 in nuclear membrane, and GFP alone in cytoplasm. Scale bar: 100 μm
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The reduced AvBD-6 and AvBD-12 showed antimicro-
bial activities similar to that of the wild-type AvBD-6
and AvBD-12, respectively (Fig. 8a). In contrast, reduced
AvBDs lost their chemotactic effect on CCR2-CHO cells
(p < 0.01, Fig. 8b). Reduction had significant negative im-
pact on the LPS-neutralizing activity of AvBD-12 (Fig. 9c
and d). For example, wild type AvBD-12 at 32 μg/ml
neutralized 74.48 % of E. coli LPS (1EU/ml) whereas
reduced AvBD-12 neutralized 28.78 % E. coli LPS at the
same peptide and LPS concentrations. Similar pattern
was observed with S. Typhimurium LPS.
TEM observations
Following treatment of S. Typhimurium with wild type
and reduced AvBDs, ultrastructural changes were ob-
served by TEM and the percentage of cells exhibiting
Fig. 6 Chemotactic activity of AvBD-6 and AvBD-12. Migration of chicken macrophage MQ-NCSU cells (a), mouse immature dendritic JAWSII cells
(b), AvBD-6 pretreated JAWSII cells (c), and AvBD-12 pretreated JAWSII cells (d), CCR2-positve CHO-K1 cells (e), CCR6-positive CHO-K1 cells (f). fLMP
and CCL20 are used as positive control for dendritic cells and CCR6-transfected CHO-K1 cells, respectively. Chemotactic activities of AvBD-6 (□)
and AvBD-12 (■) were expressed as chemotactic index (C.I.): = the number of migrated cells induced by AvBD/the number of migrated cells in
response to chemotactic buffer. Data are presented as means of five independent experiments ± SD (n = 5). Different letters indicate significant
difference (*p < 0.05). Asterisks indicate significant difference (*p < 0.05, **p < 0.01)
Yang et al. BMC Microbiology  (2016) 16:210 Page 7 of 18
ultrastructural changes were quantified based on 10 in-
dependent images per treatment group. Treatment of S.
Typhimuriun with wild type AvBD-6 or AvBD-12 re-
sulted in various ultrastructural changes, including
fuzzy membrane, vacuole formation, membrane bleb-
bing, and membrane shrinking (Fig. 10a and b). Treat-
ment of bacteria with reduced AvBD-6 and AvBD-12
caused only fuzzy membrane and leakage (Fig. 10c and
d). Approximately 29 % of bacterial cells treated with
wild type AvBDs and 27 % bacterial cells treated with
reduced AvBDs displayed ultrastructural changes.
Untreated bacteria showed intact membrane, uniform
cytoplasm without leakage of intracellular content
(Fig. 10e).
Fig. 7 Reduced AvBD-6 and −12 were structurally different from wild-types AvBDs. a RP-HPLC analysis of AvBD-6 and AvBD-12 reduced by thioredoxin
system with various concentrations of thioredoxin (0, 1, and 4 μM). Increased retention time and peak shifts indicate peptide unfolding and exposure
of hydrophobic residues caused by thioredoxin treatment. Ten microgram of peptides was completely reduced by treatment with 4 μM thioredoxin. b
Circular dichroism spectra of wild-type peptides (solid lines) and reduced peptides (dotted lines). Lines represent the average of six scans (n = 6). Wild-
type peptides displayed intracellular β-sheet structure (signal at 205, 216 nm). In contrast, reduced peptides show a signal around 195 nm, indicated
random coil structure. Molar ellipticity (θ) = deg.cm2.dmol−1
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Binding of AvBDs to bacterial genomic DNA
The ability of AvBDs to bind to bacterial genomic DNA
was analyzed by a gel retardation assay [37]. Wild-type
AvBDs at a mass ratio of 4:1 (AvBD:DNA) retarded
more than 50 % of S. Typhimurium genomic DNA mi-
gration (Fig. 11). At a mass ration of 8:1 (AvBD:DNA),
near complete retardation of genomic DNA migration
by either AvBD was observed. BSA, as a negative con-
trol, had no effect at mass ratio of 8:1 (BSA:DNA). At a
mass ratio of 4:1 (AvBD:DNA), AvBD-6 was significantly
more effective than AvBD-12 in retarding genomic DNA
migration (p < 0.01). Reduced AvBDs were less able than
their respective wild-type peptides to retard Salmonella
genomic DNA migration.
Fig. 8 Antimicrobial and chemotactic activities of reduced AvBD-6 and AvBD-12. a Comparison of antimicrobial activity of reduced (■) and wild-type
(▲) AvBDs against E. coli and S. Typhimurium. The assay was repeated three times and data are presented as means ± SD (n = 3). b Comparison of
chemotactic activities of reduced and wild-type AvBDs. Chemotactic index (C.I.) = the number of migrated CCRs expressing CHO-K1 cells induced by
AvBD/the number of migrated cells induced by chemotactic buffer. Data shown are means of three independent experiments ± SD (n = 5). Asterisks
indicate significant difference of chemotactic activity between wild-type and reduced AvBDs (*p < 0.05, **p < 0.01)
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Discussion
To understand the molecular mechanisms by which
AvBDs contribute to host innate and acquired immunity,
we have studied the transcriptional profiles of AvBD
genes and characterized the antimicrobial activities of
AvBDs with different net positive charges and tissue ex-
pression profiles [28, 29]. In the present study, we chem-
ically synthesized the mature peptides of AvBD-6 and
AvBD-12 and characterized the roles of peptide charge
and intramolecular disulfide bridges in various biological
functions. Our data indicated that synthetic AvBD-6 and
AvBD-12 were highly effective in killing E. coli, S.
Typhimurium, and S. aureus under low-salt condition.
Compared to recombinant AvBDs, synthetic AvBDs
demonstrated a potent antimicrobial activity against S.
Typhimurium which was minimally susceptible to re-
combinant AvBDs in our previous study [38]. The dis-
crepancy might be related to peptide folding because
synthetic, but not recombinant AvBDs, were subjected
to oxidative folding under optimal conditions. Consist-
ent with our previous findings with recombinant AvBDs,
the antimicrobial activity of AvBD-6 with a net positive
charge of +7 was significantly higher than that of AvBD-
12 with a net positive charge of +1. Since only two
AvBDs were included in this study, it was difficult to
truly assess the effect of charge on antimicrobial activity.
Analysis of analog peptides is in progress to determine
the contribution of charge and charge density to AvBDs’
antimicrobial activity. The antimicrobial potency of both
AvBDs against E. coli and S. Typhimurium and AvBD-12
against S. aureus was negatively affected by increased
salt concentration which was consistent with findings
from previous investigations of cationic antimicrobial
peptides [2, 15, 38, 39]. However, increased salt concen-
tration had minor impact on the bactericidal activity of
AvBD-12 against S. aureus, suggesting different mecha-
nisms are utilized by different AvBDs to kill Gram-
positive and Gram-negative bacteria. In this study, we
also found that the antimicrobial effect of AvBDs was in-
versely associated with bacterial concentration, suggest-
ing that a critical molecular ratio of AvBD:bacteria may
be needed to cause microbial membrane damage. The
antimicrobial activity of AvBDs (32 μg/ml) nearly dimin-
ished when bacterial concentration was increased from
Fig. 9 LPS-neutralizing activity of reduced AvBD-6 and AvBD-12. Comparison of LPS-neutralizing activity of reduced (■) and wild-type (▲) AvBDs.
a Reduced AvBD-6 neutralizing for E. coli O111:B4 LPS, b Reduced AvBD-6 neutralizing S. Typhimurium L6143 LPS, c Reduced AvBD-12 neutralizing
for E. coli O111:B4 LPS, d Reduced AvBD-12 neutralizing S. Typhimurium L6143 LPS. The assay was repeated three times and data are presented
as means ± SD (n = 3). Asterisks indicate significant difference of neutralizing LPS activity between wild-type and reduced AvBD-12 (**p < 0.01)
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105 CFU/ml (CFU:AvBD molecule ratio = 1:4 × 102) to
109 CFU/ml (CFU:AvBD molecule ratio = 1:4 × 106). The
present study also evaluated the antimicrobial activities
of AvBDs against clinical isolates of ESBL-positive E. coli
and K. pneumoniae and methicillin resistant S. pseudin-
termedius. Although both AvBDs showed antimicrobial
activity against ESBL-positive E. coli and K. pneumoniae,
the MIC values ranged from 128 to 256 μg/ml, as com-
pared to 4 to 64 μg/ml when the assays were conducted
under low-salt condition. It has been reported that
defensins interact electronically with bacterial membrane
and thereby destroy the integrity of the membrane to kill
the bacteria [10]. Therefore, it is important to determine
whether these peptides can disrupt the host cellular
membrane. In the present study AvBDs at a relatively
high concentration (256 μg/ml) did not affect the viabil-
ity of avian and mammalian cell lines examined. Our
data indicate that AvBDs may be potential alternative
therapeutic agent for infections caused by ESBL-
producing bacteria if their sensitivity to salt can be
modified.
It has been reported that the presence of disulfide
bridges was not essential for bovine BNDB-2 and
BNDB-12 or human hBD3 to exert their antimicrobial
function [22, 40–43]. To investigate the structure-
function relationship of AvBDs, we treated AvBDs with
Fig. 10 Transmission electron microscopy (TEM) analysis of AvBD-induced morphological changes of S. Typhimurium. Treatment of bacteria with
wild-type and reduced AvBDs at 37 °C for 30 min resulted in fuzzy membrane (1), vacuole formation (2), membrane bleb (3), morphological change
(4), and cytoplasm membrane shrinking (5). Bacteria were treated with AvBD-6 (a1-3), AvBD-12 (b1-3), reduced AvBD-6 (c), and reduced AvBD-12 (d).
Untreated bacteria showed intact membrane, uniform cytoplasm (e). Figures are representatives of 10 images per treatment group. Approximately
29 % of bacteria treated with wild type AvBDs and 27 % of bacteria treated with reduced AvBDs displayed ultrastructural changes. Scale bar: 1 μm
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the thioredoxin reductase to break the disulfide bridges
and confirmed the reduction of AvBDs by RP-HPLC and
CD [44–46]. Reduced AvBDs showed slightly reduced
potency against E. coli which was in line with a previous
report that AvBD-6 without the three disulfide bonds
expressed in Pichia Pastoris had antimicrobial activity
against S. aureus and Bacillus subtilis [47].
As a major component of Gram-negative bacteria, LPS
maintains the structural integrity of bacteria and causes
septic shock or inflammatory responses in host [48]. It
was previously shown that human defensin beta 123
(DEFB123) and recombinant human DEFB114 could in-
hibit LPS-mediated inflammation [49, 50]. It is known that
electrostatic interactions between defensins and negatively
charged LPS are prerequisite for the binding of peptides
to Gram-negative bacteria and subsequent membrane
damaging activities, and any factors (such as cationic salt
concentration) interfering with the electrostatic attraction
could inhibit defensins’ antimicrobial functions [51]. In
the present investigation, AvBD-6 with a higher net posi-
tive charge was more able than AvBD-12 to neutralize
LPS, but LPS-neutralizing capacity of neither AvBD was
affected by increased NaCl concentration. In fact, both
AvBDs were fully functional at near physiological concen-
tration of NaCl (0.8 %, 137 mM). However, the LPS-
neutralizing ability correlated with the net positive charges
of AvBDs, suggesting that electrostatic attraction is an es-
sential, but not the only factor that affects the interaction
between AvBD and LPS. This was further supported by
the fact that reduced AvBDs having the same net positive
charges as their respective wildtype peptides were less able
to neutralize LPS, specifically for AvBD-12.
Mammalian defensins can interact with cell membrane
receptors to influence diverse cellular processes includ-
ing antigen presentation, chemotaxis, and cytokine re-
lease [52, 53]. In the present investigation, both AvBDs
demonstrated mild chemotactic activities for MQ-
NCSU, and AVBD-12 at a relatively high concentration
had strong chemoattractant effect on murine immature
dendritic cells. Pretreatment JAWSII cells with AvBD
blocked AvBD-induced cell migration (p < 0.05), suggest-
ing that AvBDs interacted with murine dendritic cell
membrane component(s), likely chemokine receptors
which are highly conserved across species [54, 55]. We
then determined if CCR2 and CCR6 are the receptors
for AvBDs as indicated previously for hBD1-3 and
mBD2 and mBD14 [20–23]. Both AvBD-6 and AvBD-12
displayed strong chemotactic effect on CCR2-positive
CHO-K1 cells whereas only AvBD-6 induced moderate
chemotaxis of CCR6-positive CHO-K1 cells. CCR6 as a
G-protein-coupled receptor with seven transmembrane
domains is expressed by memory T cells, B cells, and
DCs and involved in recruiting leukocytes to sites of in-
flammation [56]. In the present study, fusion with GFP
changed the location of CCR6, which might have af-
fected the chemotactic migration of CCR6-positive
CHO-K1 cells. We conducted several independent trans-
fection assays with different clones of CCR6 plasmids,
all of which resulted in the primary expression of CCR6-
GFP in the nuclear membrane. Nonetheless, our data
show that AvBDs are broad-spectrum chemoattractant
molecules for avian and mammalian immune cells.
The dual antimicrobial mechanism involving targeting
microbial membrane and nucleic acids and enzymes
Fig. 11 AvBD interaction with S. Typhimurium genomic DNA. a Gel retardation assay revealed the binding of wild-type and reduced AvBDs to S.
Typhimurium genomic DNA. M: DNA molecular marker; lanes 1–6: the mass ratios of DNA to AvBD were 1:0, 1:0.5, 1:1, 1:2, 1:4 and 1:8, respectively;
lane 7: DNA: bovine serum albumin (BSA) at ratio of 1:8. b Densitomeric analysis of migrated DNA by ImageJ software. Density ratio between
treatment and control (lane 1) groups were calculated. Displayed values are means ± SD (n = 3). Asterisks indicate significant difference (*p < 0.05,
**p < 0.01) between wild-type and reduced AvBDs
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have been reported [57–62]. In the present study, we de-
termined the role of disulfide bridges of AvBDs in dam-
aging bacterial membrane and binding to genomic DNA.
Treatment of S. Typhimurium with AvBDs resulted in
fuzzy membrane, loss of cytoplasmic content, cytoplas-
mic membrane shrinkage, and morphological change
(Fig. 10a and b) whereas reduced AvBDs caused only
fuzzy membrane and leakage of intracellular content.
Our data suggest that wild-type AvBDs with conserved
disulfide bridges not only disrupted bacterial membrane
but also interfered with cell division and other intracel-
lular functions that cause morphological changes. In
contrast, reduced AvBDs exert their bactericidal function
mainly through membrane-lytic mechanism(s). Gel re-
tardation assay ascertained that wild type AvBDs are
more able than reduced AvBDs to bind bacterial gen-
omic DNA, potentially interfering with transcription and
translation of affected bacteria.
Conclusions
AvBD-6 and AvBD-12 exhibited strong antimicrobial ac-
tivities against E. coli, S. Typhimurium, and S. aureus
under low-salt conditions. The antimicrobial activity was
positively correlated with the peptides’ net positive
charges, inversely correlated with bacterial concentration,
strongly inhibited by NaCl at physiological concentration
(150 mM), and minimally dependent on the intramolecu-
lar disulfide bridges. LPS-neutralizing activity of AvBDs
was dependent on disulfide bridges (for AvBD-12) and un-
affected by NaCl concentration. Chemotactic activity re-
quired the tertiary structure of AvBDs but not directly
related to the peptide charge.
Functional characterization of two different AvBDs
suggests that different mechanisms could be involved in
their actions against different microbial pathogens and
microbial products (such as LPS). Data from the present
investigation provide the theoretical basis for future ap-
plication of AvBDs or their analogues as therapeutic
agents for bacterial infections and LPS-induced shock,




The mature peptides of AvBD-6 (SPIHACRYQRGVCIP
GPCRWPYYRVGSCGSGLKSCCVRNRWA [GenBank:
AAT45546.1]) and AvBD-12 (GPDSCNHDRGLCRV
GNCNPGEYLAKYCFEPVILCCKPLSPTPTK [GenBank:
AAT48936.1]) were custom synthesized using the stand-
ard solid phase 9-fluorenylmethoxycarbonyl (Fmoc)
method by LifeTein LLC (Hillsborough, NJ). Linear pep-
tides were subjected to oxidative folding to ensure the cor-
rect formation of the three disulfide bridges between Cys1-
Cys5, Cys2-Cys4 and Cys3-Cys6. Following confirmation by
mass spectrometry, AvBDs were purified by reversed-phase
high performance liquid chromatography (HPLC) and ly-
ophilized (Lifetein, Hillsborough, NJ). The purity of the
synthetic mature peptides was >98 %, the molecular
weight of AvBD-6 and AvBD-12 were 4738.57 and
4892.76, and the net charge of AvBD-6 and AvBD-12 at
pH 7.0 were +7 and +1, respectively, and they have same
hydrophobicity (Table 1).
Antimicrobial activity assay
Escherichia coli (E. coli, ATCC 25922), Salmonella en-
teric serovar Typhimurium (S. Typhimurium, ATCC
14028), and Staphylococcus aureus (S. aureus, ATCC
29213) were used to assess AvBDs’ antimicrobial activity.
Extended spectrum beta lactamase (ESBL) positive
clinical isolates of E. coli, Klebsiella pneumoniae (K.
pneumoniae), and methicillin-resistant S. pseudinetrme-
dius (Table 2) were included in the antimicrobial assays.
All bacterial strains were grown and maintained on
Trypticase Soy Agar (TSA) with 5 % Sheep Blood
(Thermo Fisher Scientific) at 37 °C.
The bactericidal activity of AvBD-6 and AvBD-12 was
determined by colony counting assay [38]. Three to five
bacterial colonies from an overnight culture on a TSA
agar plate were suspended in 5 ml sterile distilled water
to achieve a MacFarland standard of 0.5 (~108 colony
forming units per milliliter, CFU/ml). Ten microliters of
bacterial suspension was inoculated into 5 ml 100× diluted
Mueller-Hinton broth (MHB) to obtain a final concentra-
tion of approximately 2 × 105 CFU/ml. Twenty-five micro-
liters of bacterial culture was mixed with 25 μl of 2-fold
serially diluted AvBD-6 and AvBD-12 in a Nunc™ 96-well
polypropylene microtiter plate (Thermo Fisher Scientific),
and the final concentrations of AvBDs were 1, 2, 4, 8, 16,
32, 64, 128 μg/ml. Gentamycin (100 μg/ml) and peptide
dilution buffer were used as positive and negative controls,
respectively. Following an incubation at 37 °C for 3 h, 10-
fold serial dilutions of the bacterial-peptide mixture were
inoculated onto LB agar plates, then colonies were
counted after 16 h of incubation at 37 °C. The bactericidal
activity was expressed as percent of killing using the fol-
lowing formula: (CFUcontrol - CFUtreated)/CFUcontrol ×
Table 1 Amino acid sequence and properties of AvBD-6 and AvBD-12
Peptide Amino acid sequencea Length (aa) Molecular weight (Da) Charge Hydrophobicity
AvBD-6 SPIHAC1RYQRGVC2IPGPC3RWPYYRVGSC4GSGLKSC5C6VRNRWA 42 4738.57 +7 33 %
AvBD-12 GPDSC1NHDRGLC2RVGNC3NPGEYLAKYC4FEPVILC5C6KPLSPTPTKT 45 4892.76 +1 33 %
aThe three disulfide bridges formed between Cys1-Cys5, Cys2-Cys4 and Cys3-Cys6
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100 %. To investigate the effect of ionic strength on the
antimicrobial activity of AvBD-6 and AvBD-12, 5 mM,
50 mM, and 150 mM NaCl were included in the incuba-
tion buffer with peptides at antimicrobial assay.
MICs of AvBD-6 and AvBD-12 were determined using
broth microdilution method according to the guidelines
of Clinical and Laboratory Standards Institute (CLSI)
[63, 64]. Minimum inhibitory concentrations were also
determined using a low-salt Muller Hinton broth and
the values were presented as MIC-ls. In brief, AvBDs
were prepared in serial two-fold dilutions in a 96-well
polypropylene microtiter plate and inoculated with the
bacteria at a final concentration of 5 × 105 CFU/ml. The
final concentrations of AvBDs were ranging from 2 to
256 μg/ml. After incubation at 37 °C for 16 to 24 h, the
lowest concentration that completely prevented visible
bacteria growth was recorded. All antimicrobial assays
were conducted in duplicate.
Killing kinetics measurement
The killing kinetics of AvBD-6 and AvBD-12 were con-
firmed against E. coli ATCC 25922, S. Typhimurium
ATCC 14028 and S. aureus ATCC 29213. Equal volumes
(50 μl) of bacterial suspension at the concentrations 2 ×
105, 2 × 107, and 2 × 109 CFU/ml and AvBDs at a final
concentration of 32 μg/ml were co-incubated in a 96-
well polypropylene microtiter plate at 37 °C for 30, 60,
90, 120, 150, 180 min. Bacterial-peptide mixtures were
serially diluted and plated on LB agar plates. Colonies
were counted after incubation at 37 °C for 16 h. The as-
says were repeated three times with duplicate.
Limulus amoebocyte lysate assay
The LPS-neutralizing abilities of AvBDs were assessed
using a Limulus Amoebocyte Lysate (LAL) (Pierce™ LAL
Chromogenic Endotoxin Quantitation Kit, Thermo
Fisher Scientific) according to the manufacturer’s in-
structions. Briefly, equal volumes (25 μl) of AvBDs in
endotoxin-free water (final concentrations of 8, 16,
32 μg) and E. coli O111:B4 LPS or S. Typhimurium
L6143 LPS (2 EU/ml) were co-incubated at 37 °C for
30 min to permit binding of the peptide to LPS. Then,
50 μl of the assay mixture was transferred to Greiner
CELLSTAR® flat-bottom, non-pyrogenic 96-well cell cul-
ture plate (VWR, Sugar Land, TX). Fifty microliters of
2-fold serially diluted E. coli O111:B4 LPS, ranging from
0.125 to 1.0 EU/ml, were used as the standards.
Endotoxin-free water and AvBDs alone were included as
negative controls. Fifty microliters of LAL was added to
each well of the assay plate which was incubated at 37 °
C for 10 min. One hundred μl of chromogenic substrate
was then added to each well followed by incubation at
37 °C for 6 min, and addition of 50 μl of 25 % acetic acid
to stop the reaction. Color change due to enzymatic liber-
ation of p-Nitroaniline was monitored at 405 nm with
Bio-Rad Benchmark Microplate Reader (Hercules, CA).
LPS neutralizing rate was calculated as (OD405AvBDs+LPS -
OD405H2O)/(OD405LPS - OD405H2O) × 100 %. The assays
were performed three times with duplicate.
Cell culture
Chicken macrophage MQ-NCSU and HD11 cell lines
and Chinese hamster ovary (CHO)-K1 cell line were
maintained in RPMI-1640 media supplemented with
10 % fetal bovine serum (FBS), 100 U/ml penicillin and
100 μg/ml streptomycin, at 37 °C in humidified air with
5 % CO2. Additional 2 % chicken serum was added for
MQ-NCSU cells culture. Mouse immature dendritic cell
line JAWSII (ATCC CRL-11904TM) was cultured in
Alpha minimum essential medium with ribonucleosides,
deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium
pyruvate and 5 ng/ml murine Granulocyte macrophage
colony-stimulating factor (GM-CSF), supplemented with
20 % FBS, 100 U/ml penicillin and 100 μg/ml strepto-
mycin, at 37 °C in humidified air with 5 % CO2.
Table 2 Minimum Inhibitory Concentrations of AvBD-6 and AvBD-12a
Microorganism Source (Number of strains) AvBD-6 AvBD-12
MIC MIC-ls MIC MIC-ls
Gram-negative
E. coli ATCC 25922 (1) 128 4 256 32
E. coli Clinical isolates (10) 256 ≤8 256 ≤64
S. enterica serovar Typhimurium ATCC 14028 (1) ≥256 16 >256 128
K. pneumoniae Clinical isolates (10) ≥256 ≤16 >256 ≤64
Gram-positive
S. aureus ATCC 29213 (1) 256 128 >256 256
S. pseudinetrmedius Clinical isolates (10) ≥256 ≥256 >256 ≥256
aMinimum inhibitory concentrations (μg/ml) were determined using the CLSI broth microdilution method and the modified broth microdilution method using low
salt Muller Hinton Broth (MIC-ls) as described in materials and methods section. Clinical isolates were received from the Clinical Veterinary Microbiology
Laboratory of Texas A&M University
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Cell cytotoxicity
The cytotoxicity of AvBDs to four cell lines was deter-
mined using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) cell proliferation assay
(Thermo Fisher Scientific). Cells (5 × 103 cells/well) in
96-well microtiter tissue culture plates were treated with
AvBD-6 and AvBD-12 at the concentrations of 4, 16, 64,
and 256 μg/ml for 4, 12, 24, 48 h at 37 °C. After treat-
ment, 20 μl of 12 mM MTT solution was added to each
well and the palates were incubated for 4 h. The
medium in each well was replaced with dimethyl sulfox-
ide (DMSO, Sigma-Aldrich) to dissolve MTT crystals.
The plates were read using a spectrophotometer at
540 nm. The viability of treated cells was expressed as
the percentage of viability relative to the untreated con-
trol. The experiment was performed in triplicate.
Construction of pAcGFP1-N1-CCR2 and -CCR6
Total RNA was extracted from MQ-NCSU cells or chicken
liver with the Rneay® Mini kit (Qiagen), and the first-stand
cDNA was synthesized by reverse-transcription polymerase
chain reaction (RT-PCR) with SuperScript® III first-strand
synthesis system (Invitrogen) according the manufacturer’s
instruction. PCR was performed using pfu DNA polymer-
ase (Stratagene, CA) and primers containing flanking en-
zyme restriction sites XhoI and HindIII. The forward and




GTACTACAGTTTTTG-3´ and CCR6-R 5´-CCCAA
GCTTTATAGTAAAAGAAGATGCAT-3´. The PCR prod-
ucts of CCR2 and CCR6 were purified and cloned to pCR®
2.1-TOPO® vector and transformed into E. coli TOP10F´
competent cells. Plasmid DNA was isolated from the trans-
formed clones using the QIAprep® Spin Miniprep kit (Qia-
gen), and sequenced to confirm the correctness of inserts.
The CCR2 and CCR6 inserts were subcloned to eukaryotic
expression vector pAcGFP1-N1 (Clontech) between the
XhoI and HindIII restriction sites and transformed into E.
coli TOP10F´ competent cells. The recombinant pAcGFP1-
N1-CCR2 and -CCR6 plasmids were extracted and con-
firmed by PCR and digestion with XhoI and HindIII.
Transfection of CHO-K1 cells expressing CCR-2 and CCR-6
CHO-K1 cells were seeded into a 6-well-plate. After
80 % confluence, cells were transfected by pcGFP1-N1-
CCR2, pAcGFP1-N1-CCR6 and pAcGFP1-N1 (mock)
plasmids using the TransIT-CHO Transfection Kit ac-
cording to the manufacturer’s instructions (Mirus Bio
LLC, WI). After 72 h incubation, cells were harvested
and selected in 500 μg/ml G8 (Sigma-Aldrich) media.
CHO-K1 cells stably expressing CCR2 and CCR6 were
used to perform chemotaxis assay.
To verify transfection, CCRs transfected CHO-K1 cells
were cultured on a cover slide in RPMI-1640 with 10 %
FBS, 2 mM L-glutamine, 100 units/ml penicillin and
streptomycin, 500 μg/ml G8 at 37 °C in humidified air
with 5 % CO2. After 80 % confluence, cells were washed
with ice-cold phosphate buffered saline (PBS) and fixed
by methanol:acetone (v:v, 1:1). Fixed cells were then
washed twice with PBS and stained nuclei with 0.1 μg/ml
DAPI (Thermo Fisher Scientific) in PBS for 1 min, then
the cells were washed three times with PBS before micro-
scopic visualization. Wild-type CHO-K1 cells and mock
transfected cells were examined simultaneously as con-
trols. Cells were visualized and captured using Nikon
fluorescent microscope connected with Olympus DP2-
BSE software (ECLIPSE E600, Japan, 20×). In addition,
total RNAs were extracted from transfected cells and RT-
PCRs were performed to verify expression of CCR2 and
CCR6 as described in construction of pAcGFP1-N1-CCR2
and -CCR6. PCR products were subjected to gel electro-
phoresis and photographed on the FluorChem Q imaging
system (Cell Biosciences, CA).
Western blot analysis was also carried out to confirm
CCR2/CCR6 expression in CHO-K1 cells. In brief, CHO-
K1 cells were suspended in RIPA cell lysis buffer (Thermo
Fisher Scientific) for 10 min and centrifuged at 13,000 g
for 10 min at 4 °C. Protein concentration was measured
using a NanoDrop 1000 spectrophotometer at 280 nm
(Thermo Fisher Scientific). An equivalent amount of pro-
tein from each sample was run on a 12 % SDS-PAGE gel
and transferred onto a nitrocellulose membrane (Bio-
Rad). The protein fractions were probed with polyclonal
goat anti-GFP primary antibody (1:1000, Thermo Fisher
Scientific) and horseradish peroxidase (HRP)-coupled
anti-goat secondary antibody (1:500, Promega), and visual-
ized after color development with 4-Chloro-1-Naphthol
(4-CN) and 30 % hydrogen peroxide (Thermo Fisher Sci-
entific). Protein bands were photographed using
FluorChem Q imaging system (Cell Biosciences, CA).
Chemotaxis assay
Migration of MQ-NCSU cells, JAWSII cells and CCR2-/
CCR6-expressing CHO-K1 cells in response to chemo-
tactic factors was determined using a 48-well microche-
motaxis chamber technique as previously described [65].
Single cell suspension was prepared by treating cells
with a non-enzymatic cell dissociation solution (Sigma-
Aldrich), and the dissociated cells were harvested by
centrifugation and resuspended in chemotaxis assay
buffers at a final concentration of 1.5 × 106 cells/ml. The
chemotaxis buffer for MQ-NCSU and CCR2-/CCR6-ex-
pressing CHO-K1 cells was RPMI 1640 supplement with
0.1 % BSA, 100U/ml penicillin, and 100 μg/ml strepto-
mycin, and for JAWSII cells was Alpha Minimum Essen-
tial Medium containing 0.1 % BSA, 100U/ml penicillin,
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and 100 μg/ml streptomycin. In brief, 28 μl of 4-fold di-
luted AvBDs in chemotactic buffer ranging from 0.25 to
64 μg/ml was placed in the lower wells of a 48-well
microchemotaxis chamber (Neuro Probe, San Diego,
CA), and 50 μl of cell suspension was added to the
upper wells. The lower and upper compartments were
separated by a pre-coated polycarbonate membrane
(8 μm pore size) with 10 μg/ml fibronectin (BD biosci-
ences, Bedford, MA). After incubation at 37 °C for 1 to
5 h in humidified air with 5 % CO2, the membranes were
removed, topside scraped, stained with Kwik-Diff stain-
ing kit (Thermo Fisher Scientific), and counted under
light microscopy. Chemotaxis buffer and bacterial pep-
tide N-Formyl-methionyl-leucyl-phenylalanine (fMLF,
Sigma-Aldrich) were used as negative and positive con-
trols, respectively. The results were presented as chemo-
tactic index (C.I.) using the following formula: C.I. = the
number of migrated cells following treatment with
AvBDs/the number of migrated cells following treatment
with chemotactic buffer. To investigate if the peptides
directly bind to plasma membrane components, JAWSII
cells were pre-incubated with 0.25–64 μg/ml chemo-
attractant (AvBD-6 or AvBD-12) for 30 min at 37 °C in
humidified air containing 5 % CO2. Then, the chemo-
taxis assay was performed with the same procedure.
For CCR2/6 expressing CHO-K1 cells, the mock trans-
fected CHO-K1 cells were analyzed simultaneously as
negative cell control. Recombinant chicken CCL20 (In-
novative research, the chemokine ligand for CCR6) was
used as positive chemotactic agent control. C.I. = the
number of migrated CCR2/6-expressing CHO-K1 cells
following treatment with AvBDs/the number of migrated
cells following treatment with chemotactic buffer. All
chemotaxis assays were performed five times.
Reduction of AvBD peptides
Ten microgram of AvBDs were incubated with 0.8 mM
β-nicotinamide adenine dinucleotide 2’-phosphate, re-
duced (NADPH), 0.2 μM thioredoxin reductase, 0, 1, 2,
4 μM E.coli thioredoxin (Sigma-Aldrich) at 37 °C for
60 min in 0.1 M potassium phosphate-2 mM EDTA buf-
fer, pH 7.0. The incubation mixtures were analyzed using
reversed-phase high performance liquid chromatography
(RP-HPLC) and absorbance at 340 nm was monitored to
test the consumption of NADPH using a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific). The
reduced peptides were separated from thioredoxin sys-
tem by Amicon Ultra centrifuge filters with 10 kDa
membrane and 3 kDa membrane (Millipore). Natural
and reduced AvBDs were analyzed by RP-HPLC using
the Hitachi HPLC system and Phenomenex (Torrance,
CA) Luna® C18 (2) Columns (100 × 4.6 mm, 3 μm), mo-
bile phase 90 % A (water + 0.1 % (v/v) trifluoroacetic
acid (TFA)) and 10 % B (acetonitrile + 0.1 % (v/v) TFA),
under 214 nm UV wavelength, and a flow rate of 1.0 ml/
min at 25 °C. The structures of AvBDs were probed by
circular dichroism (CD) spectroscopy on a JASCO J-815
spectropolarimeter (JASCO, Easton, MD) in a 0.2 cm
quartz cell. Spectra were recorded at peptide concentra-
tions of 0.1 mg/ml diluted in a 10 mM phosphate buffer
(pH 7.4), in far-ultraviolet (UV) region from 190 to
250 nm at room temperature. Each CD spectrum was
the average of six consecutive scans, and all data were
corrected with the blank buffer and expressed as molar
ellipticity θ (deg · cm2 · mol−1).
Transmission electron microscopy (TEM)
Mid-logarithmic phase S. Typhimurium cells (1 ×
108 CFU) were treated with wild-type and reduced AvBD-
6 (16 μg/ml) and AvBD-12 (128 μg/ml) at 37 °C for
30 min in the presence of 5 mM NaCl. These AvBD con-
centrations were required to inhibit bacterial growth in
the presence of 5 mM NaCl. Bacterial cells were harvested
by centrifugation at 5, 000 g for 10 min. TEM imaging was
performed according to the procedure described by Park
and Kand [66]. In brief, samples were fixed in Karnovsky’s
reagent (2 % paraformaldehyde, 2.5 % glutaraldehyde in
0.1 M sodium cacodylate buffer, pH 7.4) and dehydrated
through a graded ethanol series of 20, 50, 70, 90 % and 3×
100 %, and then stained with 2 % uranyl acetate. Observa-
tions were made under a transmission electron micro-
scope (JEOL 1400, Japan). Untreated cells were processed
at the same time as negative control.
Gel retardation assay
The binding of AvBDs to genomic DNA of S. Typhimur-
ium was evaluated by gel retardation assay [37]. The gen-
omic DNA of S. Typhimurium was extracted using
Genomic DNA kit (Qiagen). AvBDs were mixed with
0.4 μg of genomic DNA at peptide-to-DNA ratios of 0, 0.5,
1, 2, 4 and 8 (w/w). BSA were used as negative control. The
mixture were incubated for 10 min at room temperature
and analyzed by electrophoresis on a 0.5 % agarose gel.
Densitomeric analysis of photographed gel pictures was
performed using ImageJ software (NIH, Bethesda, MD,
USA. The data was expressed as the density ratio of mi-
grated DNA with AvBDs or BSA binding to DNA without
binding. The assay was performed in triplicate.
Statistical analysis
Data were analyzed by student’s t-test or one-way ana-
lysis of variance (ANOVA) followed by Duncan’s test for
multiple comparisons using software SPSS version 19.0
(IBM Corp., Armonk, NY), and expressed as means ±
standard deviation (SD). Differences at p < 0.05 level
were considered statistically significant, and at p < 0.01
level were considered extremely significant.
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